Kush Parmar Sells 1,718 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 1,718 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $6.85, for a total value of $11,768.30. Following the completion of the sale, the director owned 2,846,592 shares in the company, valued at approximately $19,499,155.20. The trade was a 0.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Kush Parmar also recently made the following trade(s):

• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Down 0.3%

TRDA stock opened at $7.24 on Wednesday. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.45. The firm has a market cap of $281.06 million, a price-to-earnings ratio of -1.81 and a beta of -0.26. The business’s fifty day simple moving average is $6.85 and its two-hundred day simple moving average is $9.79.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. Research analysts expect that Entrada Therapeutics, Inc. will post -4.12 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on TRDA. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a report on Friday, May 8th. Finally, Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $17.50.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional investors increased their holdings during the second quarter, including Geode Capital Management, Invesco, Prudential Financial, American Century and RhumbLine Advisers. Institutional and hedge-fund ownership stands at approximately 86.39%, providing some support for the stock. Analysts’ consensus price target of $17.50 is also well above TRDA’s recent trading level, though the consensus rating is “Hold.”
• Neutral Sentiment: Entrada’s latest reported quarterly results beat expectations on earnings, with a loss of $0.95 per share versus the expected $1.06 loss. However, revenue was only $0.88 million compared with the $2.92 million consensus estimate, highlighting the company’s early-stage biotechnology profile and continuing operating losses.
• Negative Sentiment: Director Kush Parmar and major shareholder Ventures L.P. 5AM disclosed sales of 114,756 shares at an average price of $6.93, worth approximately $795,259. The filings appear to describe the same transaction through related insider reports, rather than two separate sales. The transaction reduced the holder’s reported ownership by 3.87%, leaving roughly 2.85 million shares. Entrada Therapeutics insider sale article
• Negative Sentiment: The same parties also reported sales of 1,718 shares at an average price of $6.85, valued at approximately $11,768. This reduced ownership by just 0.06%, making it relatively minor compared with the larger sale. Entrada Therapeutics insider selling alert

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds have recently modified their holdings of the business. State of Wyoming increased its holdings in Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after buying an additional 4,295 shares during the period. Russell Investments Group Ltd. lifted its holdings in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics during the 2nd quarter valued at $68,000. IHT Wealth Management LLC purchased a new position in shares of Entrada Therapeutics in the 2nd quarter valued at $72,000. Finally, Jain Global LLC purchased a new position in shares of Entrada Therapeutics in the 3rd quarter valued at $69,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.